Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck

Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck

Submitted by admin on July 24, 2019 - 10:20pm
Source: 
Xconomy
News Tags: 
Bristol-Myers Squibb
Merck
Keytruda
Opdivo
non-squamous
non-squamous non-small cell lung cancer
Headline: 
Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck
snippet: 

Bristol-Myers Squibb (NYSE: BMY) this afternoon revealed yet another setback for its cancer immunotherapy nivolumab (Opdivo) in lung cancer, boosting the outlook for rival Merck.

Do Not Allow Advertisers to Use My Personal information